Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
about
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model.Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesisModel of translational cancer research in multiple myeloma.Regulation of the G-protein regulatory-Gαi signaling complex by nonreceptor guanine nucleotide exchange factors.Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma.Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunityClinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates.Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.Group II activators of G-protein signalling and proteins containing a G-protein regulatory motif.Latest advances and current challenges in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.The effects of microRNAs on glucocorticoid responsiveness.Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.Mechanisms of Resistance in Multiple Myeloma.Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.Population-based comparative analysis of differentially expressed genes between Kashin-Beck disease grades I and II.Transcriptomic analysis of skeletal muscle from beef cattle exposed to illicit schedules containing dexamethasone: identification of new candidate biomarkers and their validation using samples from a field monitoring trial.Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Methylation markers in the clinical management of leukemia patients: wave of the future or just damp squib?Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myelomaHistone deacetylase 6 in cancer
P2860
Q27692033-FC79DB1F-DAA6-48BC-B612-EF7D18DD621BQ34460989-A51F67F6-9BFE-4569-B45A-B7ED3FF8640CQ35180104-1B011871-B006-4375-BAA9-92CACE0669E1Q36089332-AA3A3013-F37B-49CC-9846-AA1F98914F46Q36498784-4FE06743-94A2-4A45-8BA6-9DAB1CCF1A4EQ36579455-633CF1B9-9415-4D62-A886-0F089C218E62Q36855799-AAB4ED50-FC87-4019-90D7-88B682AC7F98Q37006888-BE82A8D3-112C-4023-84BF-31E83D8CA70DQ37142367-C9E90D1B-155C-42E7-B298-E425AF471C29Q37142441-442D4CE5-3629-45C6-BD30-DE0039B415DFQ37211962-1477D877-CBE8-4F2D-927E-124F4AC4C6B2Q37392634-DB449485-25DA-4228-8968-D247E9C28FDFQ37505517-95A03AEF-F48B-40F1-B6FB-F5BAD2415FCBQ37880248-77264624-9533-45C1-BA67-B3FD585E6279Q37986287-9A80AD88-0C8E-4126-B62F-BF57A3DE8AF7Q38037600-45C2F1DD-8D77-4E02-8FD6-06CFFDBCB08FQ38108391-516504A2-D49C-4DEF-936C-A24231D0B1B5Q38161731-B0BD34A6-505F-447A-9941-13A8F14EF5DCQ38746789-A3A7C466-D026-4C61-BE87-BC9A08A82B73Q39137683-6AC8E687-B208-4042-88CC-EBFDC34F5E42Q39185604-79F4E11C-599D-4853-879C-06E1627FEE44Q39261435-D88071BD-3A95-415A-8E1D-DF229FBA97F9Q39379624-F0E250BA-9DF4-4924-ADEE-C80C0737B8E7Q40107591-83A8E991-1DA7-4E34-BA0C-8810E064B79FQ40751518-D294957D-D087-4228-BB0A-22E7F34F8BC1Q40914883-90251E6E-B250-4C90-A90D-375680275BD2Q41770950-56A815C9-35DF-4C29-988F-7C330F8A20CCQ51655926-E9D40F48-8205-4BB6-9DC8-996065F2437FQ58756391-4F8AD28A-40EF-49A8-94FC-9BB3B9285D28Q58768571-F46F7A08-D447-4560-B1AA-0956D36F171B
P2860
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Genomic screening for genes si ...... esistance in multiple myeloma.
@en
Genomic screening for genes si ...... esistance in multiple myeloma.
@nl
type
label
Genomic screening for genes si ...... esistance in multiple myeloma.
@en
Genomic screening for genes si ...... esistance in multiple myeloma.
@nl
prefLabel
Genomic screening for genes si ...... esistance in multiple myeloma.
@en
Genomic screening for genes si ...... esistance in multiple myeloma.
@nl
P2093
P921
P1476
Genomic screening for genes si ...... resistance in multiple myeloma
@en
P2093
Hajime Sakai
Hideki Asaoku
Hiromu Suzuki
Hiroshi Yasui
Isao Tarasawa
Kohzoh Imai
Minoru Toyota
Mitsuru Mori
Reo Maruyama
Tadao Ishida
P304
P356
10.1158/1078-0432.CCR-08-3336
P407
P577
2009-06-23T00:00:00Z